IMAC Holdings, Inc.

IMAC Holdings, Inc. is a U.S.-based specialty healthcare and life sciences company that now operates primarily through Ignite Proteomics, LLC. Ignite uses a patented RPPA proteomics platform to measure protein signaling and support oncology treatment decisions and biopharmaceutical drug development, while the legacy IMAC clinical operations remain part of the consolidated structure.

−7 611,5 %

−323,7 %

−12 554,9 %

0.09

0.09

— IMAC Holdings, Inc.
%
Proteomics and oncology testing70% RPPA-based laboratory testing that quantifies protein signaling for cancer care and research.
Biopharmaceutical research services20% Analytical services used by drug developers for biomarker and translational research.
Clinical healthcare services10% Legacy outpatient and rehabilitation services billed to patients and third-party payers.

The company sells primarily to oncology clinicians, hospitals, and biopharmaceutical companies that need...

  • Oncology providersprimary

    Clinicians and care centers that use Ignite's RPPA data to support cancer treatment decisions.

  • Biopharmaceutical companiesprimary

    Drug developers that buy protein-signaling analysis for translational research and development.

  • Patients and payerssecondary

    Patients and reimbursement sources tied to legacy outpatient and rehabilitation services.

IMAC Holdings is headquartered in the United States and its disclosed business activity is overwhelmingly U.S.-based...

  • •United States is the core operating and revenue market
  • •Laboratory growth depends on U.S. financing and staffing conditions
  • •Clinical collections come from U.S. private and government payers
  • •No meaningful country-level revenue disclosure was provided
  • •Geography is operationally concentrated rather than globally diversified

Management is focused on funding the growth of its recently acquired laboratory and building out the Ignite Proteomics...

01
Secure financingshort-term

The company needs external capital to fund laboratory expansion and ongoing operations.

02
Commercialize Ignite Proteomicsmedium-term

Revenue is minimal, so adoption of the RPPA platform is essential to create scale.

03
Build operating capacityshort-term

Laboratory and sales staffing are needed to execute growth and manage overhead.

The company faces going-concern and liquidity risk because it continues to burn cash and depends on external financing...

critical

Insufficient financing

Management says additional capital is needed to fund future operations and laboratory growth.

Scope
Laboratory expansion and ongoing corporate overhead
Materiality
high
critical

Going-concern uncertainty

The company disclosed substantial doubt about its ability to continue as a going concern.

Scope
Entire business if funding is not secured
Materiality
high
high

Commercial adoption risk

Revenue is extremely small, so the RPPA platform must gain market acceptance to scale.

Scope
Ignite Proteomics revenue growth
Materiality
high
medium

Specialized labor shortages

The company needs skilled laboratory and sales personnel at acceptable cost.

Scope
Operating capacity and overhead
Materiality
medium
Revenue recognition and collectability
Can affect reported revenue, receivables, and cash flow
Impairment of property and equipment
Can create sudden losses and reduce asset base
Going-concern disclosures
Affects investor assessment of liquidity and valuation
Discontinued operations
Can make trend analysis of core operations harder

Immunome Inc.

IMNM · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

INCYTE CORP

INCY · Services-Commercial Physical & Biological Research

IMMUNIC, INC.

IMUX · Pharmaceutical Preparations

Bolt Biotherapeutics, Inc.

BOLT · Pharmaceutical Preparations

: 28/04/2026